The IQ-SET India Study: A Multicentric, Retrospective, Observational Data Analysis Evaluating the Safety, Efficacy, and Tolerability of InsuQuick® (Insulin Aspart 100 U/mL) in Subjects with Type 2 Diabetes Mellitus
Journal of Diabetology · 2026-07 · 17 (4) · 347-352
DOI: 10.4103/jod.jod_202_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetology, online erschienen am 28.07.2026. Verfasst von Supratik Bhattacharyya und 24 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
India carries a disproportionately high burden of type 2 diabetes mellitus (T2DM), characterized by early onset, suboptimal glycemic control, and delayed insulin initiation. High treatment costs and limited access further worsen outcomes, particularly among lower-income groups. Biosimilar insulins such as InsuQuick ® (insulin aspart 100 U/mL), approved for use in India, offer an accessible and affordable alternative.
Objective
To evaluate the real-world safety, effectiveness, and tolerability of InsuQuick ® (insulin aspart 100 U/mL), a biosimilar rapid-acting insulin, in Indian adults with inadequately controlled T2DM. Materials and Methods: A retrospective, multicentric, observational study was conducted across 25 Indian clinical sites. Adults aged 18–65 years with T2DM and baseline glycated hemoglobin (HbA1c) between 7.1% and 12.0% were included. All received InsuQuick ® as part of ongoing diabetes management, newly initiated or continued at the physician’s discretion. Glycemic outcomes were evaluated over 16 weeks.
Results
Of 477 patients, 69.2% achieved HbA1c < 7.1%. Mean reductions were observed in HbA1c (−1.95%), fasting plasma glucose (−57.1 mg/dL), and postprandial glucose (−102.2 mg/dL; P < 0.0001). Efficacy was consistent across subgroups with varying disease duration, comorbidities, or prior basal insulin use. Adverse events occurred in 6.1%, including 1.3% with mild hypoglycemia; none were serious.
Conclusion
InsuQuick ® demonstrated consistent and clinically meaningful glycemic improvements across diverse patient subgroups in real-world Indian settings. Its favorable safety profile and effectiveness suggest its potential as an accessible, cost-effective alternative for insulin intensification in routine clinical care. These findings support broader adoption of biosimilar insulin therapies to address the diabetes burden in low-resource settings.
Zitieren
APA
Bhattacharyya, S., Chatterjee, S., Jadhav, A. A., Patnala, S., Chakravarthy, R., Anantharaman, R., Somani, S., Pamnani, H., Chawla, P., Verma, S., Wadhawan, P., Basavaraj, G. S., Samudra, K., Balamurugan, R., Gupta, P. K., Kharche, K., Asalkar, A., Nishitha, D., Gupta, R., …, & Gupta, A. (2026). The IQ-SET India Study: A Multicentric, Retrospective, Observational Data Analysis Evaluating the Safety, Efficacy, and Tolerability of InsuQuick® (Insulin Aspart 100 U/mL) in Subjects with Type 2 Diabetes Mellitus. Journal of Diabetology, 17(4), 347-352. https://doi.org/10.4103/jod.jod_202_25
Vancouver
Bhattacharyya S, Chatterjee S, Jadhav AA, Patnala S, Chakravarthy R, Anantharaman R, et al. The IQ-SET India Study: A Multicentric, Retrospective, Observational Data Analysis Evaluating the Safety, Efficacy, and Tolerability of InsuQuick® (Insulin Aspart 100 U/mL) in Subjects with Type 2 Diabetes Mellitus. Journal of Diabetology. 2026;17(4):347-352. doi:10.4103/jod.jod_202_25
BibTeX
@article{Bhattacharyya2026,
author = {Bhattacharyya, Supratik and Chatterjee, Sudip and Jadhav, Abhijit A. and Patnala, Sreedevi and Chakravarthy, Rooban and Anantharaman, R. and Somani, Shrikant and Pamnani, Harsha and Chawla, Purvi and Verma, Shivendra and Wadhawan, Paawan and Basavaraj, G. S. and Samudra, Kirti and Balamurugan, R. and Gupta, P. K. and Kharche, Kishor and Asalkar, Amit and Nishitha, Desu and Gupta, Rajat and Subbiah, V. R. and Bhograj, Abhijit and Prasad, G. M. and Srinath, M. and Jaganmohan, Balaji and Gupta, Amit},
title = {The IQ-SET India Study: A Multicentric, Retrospective, Observational Data Analysis Evaluating the Safety, Efficacy, and Tolerability of InsuQuick® (Insulin Aspart 100 U/mL) in Subjects with Type 2 Diabetes Mellitus},
journal = {Journal of Diabetology},
year = {2026},
volume = {17},
number = {4},
pages = {347--352},
doi = {10.4103/jod.jod_202_25}
}
EUVIMED